| P2093 | author name string | Jie Liu | |
| | Shaohua Li | |
| | Yanmei Qi | |
| | Leonard Y Lee | |
| | Saum A Rahimi | |
| | Joshua Chao | |
| | Mark P Scheuerman | |
| P2860 | cites work | The lipid phosphatase activity of PTEN is critical for its tumor supressor function | Q22007981 |
| | IRSp53/Eps8 complex is important for positive regulation of Rac and cancer cell motility/invasiveness | Q24300415 |
| | PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling | Q24303571 |
| | Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1 | Q24321968 |
| | Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN | Q24322051 |
| | P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 |
| | Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner | Q24337323 |
| | Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells | Q24647546 |
| | The epithelial-mesenchymal transition generates cells with properties of stem cells | Q24650786 |
| | PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration | Q24677034 |
| | Prospective identification of tumorigenic breast cancer cells | Q24683474 |
| | Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity | Q26851620 |
| | Phosphoregulation of the WAVE regulatory complex and signal integration | Q26863403 |
| | Novel roles of formin mDia2 in lamellipodia and filopodia formation in motile cells | Q27333967 |
| | PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation | Q27852528 |
| | Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer | Q27852608 |
| | PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 |
| | Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation | Q28116257 |
| | Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity | Q28145076 |
| | EPS8 and E3B1 transduce signals from Ras to Rac | Q28145106 |
| | Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian enabled (Mena) by c-Abl kinase | Q28188375 |
| | Abi1 is essential for the formation and activation of a WAVE2 signalling complex | Q28253079 |
| | Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss | Q28274165 |
| | Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling | Q28475546 |
| | Pten is essential for embryonic development and tumour suppression | Q28509238 |
| | Sra-1 and Nap1 link Rac to actin assembly driving lamellipodia formation. | Q28588154 |
| | An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization | Q28593023 |
| | The functions and regulation of the PTEN tumour suppressor | Q29615536 |
| | In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells | Q29616498 |
| | Generation of breast cancer stem cells through epithelial-mesenchymal transition | Q29619717 |
| | Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties | Q29636244 |
| | An overview of epithelio-mesenchymal transformation | Q30014826 |
| | Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. | Q30167694 |
| | Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1. | Q30167967 |
| | Essential role for Abi1 in embryonic survival and WAVE2 complex integrity | Q30499934 |
| | Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme | Q33406936 |
| | Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 |
| | Epithelial to mesenchymal transition and breast cancer. | Q33627118 |
| | Activation of the WAVE complex by coincident signals controls actin assembly | Q33638097 |
| | Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis | Q33762003 |
| | Isolation of two human tumor epithelial cell lines from solid breast carcinomas | Q34160332 |
| | The PTEN-PI3K pathway: of feedbacks and cross-talks | Q34828662 |
| | Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. | Q35000243 |
| | Talin1 regulates integrin turnover to promote embryonic epithelial morphogenesis | Q35139916 |
| | PTEN induces apoptosis and cavitation via HIF-2-dependent Bnip3 upregulation during epithelial lumen formation | Q35349562 |
| | Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors | Q35535953 |
| | Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition | Q35558027 |
| | PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner | Q57591077 |
| | Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Q87702640 |
| | Mesenchymal-epithelial transition in development and reprogramming | Q90854375 |
| | PTEN-opathies: from biological insights to evidence-based precision medicine | Q90918120 |
| | PTEN dephosphorylates Abi1 to promote epithelial morphogenesis | Q97554573 |
| | PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors | Q35838565 |
| | Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells | Q35871737 |
| | Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance | Q36092560 |
| | Epithelial-mesenchymal transition, cancer stem cells and treatment resistance | Q36393056 |
| | Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton | Q36443397 |
| | Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1. | Q36827924 |
| | Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 |
| | An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 |
| | Hereditary breast cancer: new genetic developments, new therapeutic avenues | Q37199029 |
| | Integrins are required for the differentiation of visceral endoderm | Q37271595 |
| | Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress | Q37380066 |
| | Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways | Q37425090 |
| | Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and is required for invadopodia formation, extracellular matrix degradation and tumor growth of human breast cancer cells | Q37472144 |
| | The calpain system and cancer. | Q37867486 |
| | Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. | Q37961283 |
| | Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling | Q38012229 |
| | A detailed mammosphere assay protocol for the quantification of breast stem cell activity. | Q38016117 |
| | Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). | Q38396745 |
| | NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype | Q38440209 |
| | EMT: 2016. | Q38883448 |
| | Vimentin 3, the new hope, differentiating RCC versus oncocytoma | Q39010437 |
| | Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells | Q39330537 |
| | PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs | Q39584693 |
| | Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. | Q39774233 |
| | In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 |
| | The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration | Q40002542 |
| | Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion | Q40064550 |
| | Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway | Q40515874 |
| | Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. | Q40587498 |
| | Enhanced expression and secretion of an epithelial membrane antigen (MA5) in a human mucinous breast tumor line (BT549). | Q41752903 |
| | Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. | Q43290574 |
| | Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. | Q44615027 |
| | Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway | Q45908947 |
| | Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. | Q46011005 |
| | The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer | Q47106625 |
| | Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. | Q47148689 |
| | MYC and tumor metabolism: chicken and egg. | Q47414931 |
| | EMT in cancer | Q47736873 |
| | Actin and serum response factor transduce physical cues from the microenvironment to regulate epidermal stem cell fate decisions | Q48532732 |
| | Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. | Q54502551 |
| | Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation. | Q54635876 |
| P433 | issue | 1 | |
| P921 | main subject | neoplastic stem cells | Q1638475 |
| P304 | page(s) | 12685 | |
| P577 | publication date | 2020-07-29 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | PTEN suppresses epithelial-mesenchymal transition and cancer stem cell activity by downregulating Abi1 | |
| P478 | volume | 10 | |